Results 131 to 140 of about 12,182,524 (404)
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva+5 more
wiley +1 more source
Background As a member of the family of the YTH domain and a an m6A reader, YTHDF3 is implicated in cancer and inflammatory diseases. However, its function in ankylosing spondylitis (AS)—a chronic inflammatory disease marked by aberrant bone formation—is
Bole Zhou+6 more
doaj +1 more source
Bone Diseases in Patients with Chronic Liver Disease
Osteoporosis is a frequently observed complication in patients with chronic liver disease, particularly liver cirrhosis and cholestatic liver diseases. In addition, osteoporosis is critical in patients receiving a liver transplant.
Hae Min Jeong, D. J. Kim
semanticscholar +1 more source
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon+13 more
wiley +1 more source
Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle [PDF]
The estimates of global incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) are worrisome, due to the parallel burden of obesity and its metabolic complications. Indeed, excess adiposity and insulin resistance represent two of the major
Chiesa, Claudio+4 more
core +2 more sources
Vanishing bone disease (Gorham-Stout syndrome): A review of a rare entity.
Vanishing bone disease (Gorham-Stout syndrome) is a rare entity of unknown etiology, characterized by destruction of osseous matrix and proliferation of vascular structures, resulting in destruction and absorption of bone.
V. Nikolaou+3 more
semanticscholar +1 more source
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo+11 more
wiley +1 more source
AbstractBone impairment associated with Cushing’s disease (CD) is a complex disorder, mainly involving deterioration of bone quality and resulting in an increased fracture rate, often despite normal bone mineral density. Bone complications are common in patients with CD at the time of diagnosis but may persist even after successful treatment.
Zdrojowy-Wełna, Aleksandra+2 more
openaire +3 more sources
Bone disease in primary hyperparathyroidism.
Bone disease in severe primary hyperparathyroidism (PHPT) is described classically as osteitis fibrosa cystica (OFC). Bone pain, skeletal deformities and pathological fractures are features of OFC.
F. Bandeira+6 more
semanticscholar +1 more source
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim+11 more
wiley +1 more source